Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
C$0.44
+2.3%
C$0.42
C$0.36
C$0.73
C$8.60M1.6617,543 shs3,500 shs
MEM
Matthews Emerging Markets Equity Active ETF
$28.91
+1.4%
$28.90
$24.01
$29.90
$57.82M1.0811,520 shs3,976 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
-1.15%+2.38%+7.50%-20.37%-33.85%
MEM
Matthews Emerging Markets Equity Active ETF
+1.45%-0.27%-1.68%+5.15%+6.98%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/AN/AN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
0.00
N/A$32.0110.73% Upside

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
C$17.52M0.49C$0.37 per share1.20C$0.94 per share0.47
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
-C$1.99M-C$0.10N/AN/A-11.33%-9.95%-4.61%5/9/2024 (Estimated)
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/A15.28N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/AN/AN/AN/AN/A
MEM
Matthews Emerging Markets Equity Active ETF
$0.140.48%N/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
6.66
3.80
2.29
MEM
Matthews Emerging Markets Equity Active ETF
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/A
MEM
Matthews Emerging Markets Equity Active ETF
N/A

Insider Ownership

CompanyInsider Ownership
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
10.32%
MEM
Matthews Emerging Markets Equity Active ETF
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
6219.54 millionN/ANot Optionable
MEM
Matthews Emerging Markets Equity Active ETF
N/A2.00 millionN/ANot Optionable

IXI, MEM, CTX, LCT, and CDY Headlines

No headlines for this company have been tracked by MarketBeat.com

Top Headlines

All Headlines

Company Descriptions

Crescita Therapeutics logo

Crescita Therapeutics

TSE:CTX
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Matthews Emerging Markets Equity Active ETF

NYSEARCA:MEM
The Matthews Emerging Markets Equity Active ETF (MEM) is an exchange-traded fund that mostly invests in total market equity. The fund is actively managed to invest in emerging market companies with perceived sustainable growth potential. MEM was launched on Jul 13, 2022 and is managed by Matthews.